News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
Press Release
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
News
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
Press Release
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
News
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now
Press Release
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now
News
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
Press Release
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
Press Release
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now
Press Release
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now